How I treat the older patient with acute myeloid leukemia
Open Access
- 29 January 2015
- journal article
- case report
- Published by American Society of Hematology in Blood
- Vol. 125 (5), 767-774
- https://doi.org/10.1182/blood-2014-08-551499
Abstract
Acute myeloid leukemia (AML) in older patients presents a notable therapeutic challenge to the clinical hematologist. The clinical biology of AML among patients is highly heterogeneous. Interpatient variations are relevant for prognosis and treatment choice. Outcome of treatment for patients of advanced age is often compromised by comorbid conditions and an enhanced susceptibility to toxicities from therapy. Here we present selected clinical vignettes that highlight distinct representative situations derived from clinical practice. The vignettes are specifically discussed in light of the perspective of treating older patients with leukemia. We review the clinical significance of various cytogenetic and molecular features of the disease, and we examine the various currently available treatment options as well as the emerging prognostic algorithms that may offer guidance in regard to personalized therapy recommendations. The dilemmas in tailoring treatment selection in this category of patients with AML are the central theme in this discussion.Keywords
This publication has 62 references indexed in Scilit:
- Outcome of older patients with acute myeloid leukemiaCancer, 2013
- Acute myeloid leukemia in the real world: why population-based registries are neededBlood, 2012
- Most 70- to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatmentBlood, 2011
- Acute myeloid leukaemia in the elderly: a reviewBritish Journal of Haematology, 2011
- Therapeutic Advances in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2011
- Age-Specific Differences in Oncogenic Pathway Dysregulation in Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2009
- AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significanceBlood, 2009
- High-Dose Daunorubicin in Older Patients with Acute Myeloid LeukemiaNew England Journal of Medicine, 2009
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia RegistryBlood, 2009
- Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005Blood, 2009